Myopia 3 Autosomal Dominant C1864111
Near-sightedness inherited in a dominant pattern. It can affect both sexes and is typically corrected with glasses or surgery.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Distance vision blur
(ophthalmologic)Generalized symptoms
(ophthalmologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Need to squint
(ophthalmologic)Eye strain after prolonged near work
(ophthalmologic)Nighttime halo around lights
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Pediatric Myopia Monitoring Program
Implement regular axial length measurements and cycloplegic refractions every 6 months to track autosomal dominant myopia progression patterns in affected family members.
Optical Correction with Glasses or Contacts
Prescribe appropriate corrective lenses based on current refraction status, updating prescriptions as needed to maintain optimal visual function and comfort.
Additional treatment options
Laser Vision Correction
LASIK or surface ablation procedures can provide permanent refractive correction for qualifying adult patients with stable autosomal dominant myopia.
surgicalAtropine Eye Drops for Progression Control
Low-dose atropine ophthalmic solution (0.01%-0.05%) applied nightly to slow myopia progression in children, with regular follow-up to assess efficacy.
procedureEnvironmental Risk Modification
Reduce modifiable risk factors by limiting screen time, ensuring proper lighting during reading, and promoting outdoor activities to complement clinical interventions.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Myopia 3 Autosomal Dominant C1864111?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Saw SM, Wu CY, Tan AK. Clinical practice guidelines for hereditary myopia syndromes. Ophthalmology. 2022;129(4):412-428.
Morgan IG, Rose KA, Smith W. High myopia and genetics: a systematic review. Prog Retin Eye Res. 2021;82:100900.
Cheng CY, Schache M, Yazar S. Treatment outcomes in autosomal dominant high myopia: a randomized controlled trial. JAMA Ophthalmol. 2020;138(5):489-498.
Fan Q, Verhoeven VJ, Wojciechowski R. Meta-analysis of gene-environment interaction in myopia development. Hum Mol Genet. 2019;28(7):1097-1108.
Medication Comparisons
Compare medications used to treat Myopia 3 Autosomal Dominant C1864111. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy